Immunogenicity of decidual stromal cells in an epidermolysis bullosa patient and in allogeneic hematopoietic stem cell transplantation patients

Stem Cells and Development

Volumn 24, Issue 12, 2015, Pages 1471-1482

  Kaipe, Helen ^a   Carlson, Lena Maria ^b   Erkers, Tom ^a   Nava, Silvia ^a   Mollden, Pia ^a   Gustafsson, Britt ^a   Qian, Hua ^c   Li, Xiaoguang ^c   Hashimoto, Takashi ^c   Sadeghi, Behnam ^a   Alheim, Mats ^a   Ringden, Olle ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN ANTIBODY; KALININ; ANTIIDIOTYPIC ANTIBODY; BOVINE SERUM ALBUMIN; CELL ADHESION MOLECULE; HLA ANTIGEN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; CASE REPORT; CONTROLLED STUDY; DECIDUA; EPIDERMOLYSIS BULLOSA; FEMALE; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HEMORRHAGIC CYSTITIS; HUMAN; HUMAN CELL; IMMUNOGENICITY; INFANT; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; STROMA CELL; ADOLESCENT; ADULT; ADVERSE EFFECTS; AGED; ANIMAL; BLOOD; CHILD; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOGENETICS; IMMUNOLOGY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; MIDDLE AGED; MONONUCLEAR CELL; PATHOLOGY; TRANSPLANTATION; XENOGRAFT;

BOVINAE; MUS;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; CELL ADHESION MOLECULES; CHILD; DECIDUA; EPIDERMOLYSIS BULLOSA; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROGRAFTS; HLA ANTIGENS; HUMANS; IMMUNOGENETIC PHENOMENA; INFANT; LEUKOCYTES, MONONUCLEAR; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MIDDLE AGED; SERUM ALBUMIN, BOVINE;

EID: 84926325288     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2014.0568     Document Type: Article

References (49)

1. Fine JD, L Bruckner-Tuderman, RA Eady, EA Bauer, JW Bauer, C Has, A Heagerty, H Hintner, A Hovnanian, et al. (2014). Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol 70:1103-1126.
2. Uitto J, JA McGrath, U Rodeck, L Bruckner-Tuderman and EC Robinson. (2010). Progress in epidermolysis bullosa research: toward treatment and cure. J Invest Dermatol 130:1778-1784.
3. Yuen WY, HH Lemmink, KK van Dijk-Bos, RJ Sinke and MF Jonkman. (2011). Herlitz junctional epidermolysis bullosa: diagnostic features, mutational profile, incidence and population carrier frequency in the Netherlands. Br J Dermatol 165:1314-1322.
4. Kho YC, LM Rhodes, SJ Robertson, J Su, G Varigos, I Robertson, P Hogan, D Orchard and DF Murrell. (2010). Epidemiology of epidermolysis bullosa in the antipodes: the Australasian Epidermolysis Bullosa Registry with a focus on Herlitz junctional epidermolysis bullosa. Arch Dermatol 146:635-640.
5. Yan EG, JJ Paris, J Ahluwalia, AT Lane and AL Bruckner. (2007). Treatment decision-making for patients with the Herlitz subtype of junctional epidermolysis bullosa. J Perinatol 27:307-311.
6. Wagner JE, A Ishida-Yamamoto, JA McGrath, M Hordinsky, DR Keene, DT Woodley, M Chen, MJ Riddle, MJ Osborn, et al. (2010). Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med 363:629-639.
7. Kopp J, RE Horch, KD Stachel, W Holter, MA Kandler, H Hertzberg, W Rascher, V Campean, R Carbon and H Schneider. (2005). Hematopoietic stem cell transplantation and subsequent 80% skin exchange by grafts from the same donor in a patient with Herlitz disease. Transplantation 79:255-256.
8. Lo V, I Lara-Corrales, A Stuparich and E Pope. (2010). Amniotic membrane grafting in patients with epidermolysis bullosa with chronic wounds. J Am Acad Dermatol 62: 1038-1044.
9. Petrof G, M Martinez-Queipo, JE Mellerio, P Kemp and JA McGrath. (2013). Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomized, vehicle-controlled trial. Br J Dermatol 169:1025-1033.
10. Conget P, F Rodriguez, S Kramer, C Allers, V Simon, F Palisson, S Gonzalez and MJ Yubero. (2010). Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa. Cytotherapy 12:429-431.
11. Perdoni C, JA McGrath and J Tolar. (2014). Preconditioning of mesenchymal stem cells for improved transplantation efficacy in recessive dystrophic epidermolysis bullosa. Stem Cell Res Ther 5:121.
12. Ringden O, T Erkers, S Nava, M Uzunel, E Iwarsson, R Conrad, M Westgren, J Mattsson and H Kaipe. (2013). Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease. Stem Cells 31:592-601.
13. Erkers T, H Kaipe, S Nava, P Mollden, B Gustafsson, R Axelsson and O Ringden. (2015). Treatment of severe chronic graft-versus-host disease with decidual stromal cells and tracing with indium radiolabeling. Stem Cells Dev 24:253-263.
14. Karlsson H, T Erkers, S Nava, S Ruhm, M Westgren and O Ringden. (2012). Stromal cells from term fetal membrane are highly suppressive in allogeneic settings in vitro. Clin Exp Immunol 167:543-555.
15. Tse WT, JD Pendleton, WM Beyer, MC Egalka and EC Guinan. (2003). Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75:389-397.
16. Le Blanc K, C Tammik, K Rosendahl, E Zetterberg and O Ringden. (2003). HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 31:890-896.
17. Beggs KJ, A Lyubimov, JN Borneman, A Bartholomew, A Moseley, R Dodds, MP Archambault, AK Smith and KR McIntosh. (2006). Immunologic consequences of multiple, high-dose administration of allogeneic mesenchymal stem cells to baboons. Cell Transplant 15:711-721.
18. Eliopoulos N, J Stagg, L Lejeune, S Pommey and J Galipeau. (2005). Allogeneic marrow stromal cells are immune rejected by MHC class I-and class II-mismatched recipient mice. Blood 106:4057-4065.
19. Nauta AJ, G Westerhuis, AB Kruisselbrink, EG Lurvink, R Willemze and WE Fibbe. (2006). Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 108:2114-2120.
20. Kaipe H, T Erkers, B Sadeghi and O Ringden. (2014). Stromal cells-are they really useful for GVHD? Bone Marrow Transplant 49:737-743.
21. Sundin M, O Ringden, B Sundberg, S Nava, C Gotherstrom and K Le Blanc. (2007). No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica 92:1208-1215.
22. Ringden O, M Remberger, G Dahllof, K Garming-Legert, H Karlsson, P Svenberg, M Uhlin, M Uzunel and J Mattsson. (2011). Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders. Eur J Haematol 87:503-509.
23. Ringden O, T Erkers, J Aschan, K Garming-Legert, K Le Blanc, H Hagglund, B Omazic, P Svenberg, G Dahllof, et al. (2013). A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation. J Intern Med 274: 153-162.
24. Hisamatsu Y, T Nishiyama, S Amano, C Matsui, R Ghohestani and T Hashimoto. (2003). Usefulness of immunoblotting using purified laminin 5 in the diagnosis of anti-laminin 5 cicatricial pemphigoid. J Dermatol Sci 33:113-119.
25. Hirako Y, Y Yonemoto, T Yamauchi, Y Nishizawa, Y Kawamoto and K Owaribe. (2014). Isolation of a hemidesmosome-rich fraction from a human squamous cell carcinoma cell line. Exp Cell Res 324:172-182.
26. Miyamoto S, D Chikazu, T Yasuda, A Enomoto, IT Oh, Y Hirako, A Tsuchisaka, A Yasukochi, R Sogame, et al. (2014). A case of oral mucous membrane pemphigoid with IgG antibodies to integrin alpha6beta4. Br J Dermatol 145: 998-1004.
27. Le Blanc K, F Frassoni, L Ball, F Locatelli, H Roelofs, I Lewis, E Lanino, B Sundberg, ME Bernardo, et al. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371:1579-1586.
28. de la Portilla F, F Alba, D Garcia-Olmo, JM Herrerias, FX Gonzalez and A Galindo. (2013). Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis 28:313-323.
29. Eckert MA, Q Vu, K Xie, J Yu, W Liao, SC Cramer and W Zhao. (2013). Evidence for high translational potential of mesenchymal stromal cell therapy to improve recovery from ischemic stroke. J Cereb Blood Flow Metab 33:1322-1334.
30. Takashima S,M Yasuo, N Sanzen, K Sekiguchi, MOkabe, T Yoshida, A Toda and T Nikaido. (2008). Characterization of laminin isoforms in human amnion. Tissue Cell 40:75-81.
31. Tolar J, A Ishida-Yamamoto, M Riddle, RT McElmurry, M Osborn, L Xia, T Lund, C Slattery, J Uitto, et al. (2009). Amelioration of epidermolysis bullosa by transfer of wildtype bone marrow cells. Blood 113:1167-1174.
32. Yuen WY, JC Duipmans, B Molenbuur, I Herpertz, JM Mandema and MF Jonkman. (2012). Long-term follow-up of patients with Herlitz-type junctional epidermolysis bullosa. Br J Dermatol 167:374-382.
33. Chang CJ,ML Yen, YC Chen, CC Chien, HI Huang, CH Bai and BL Yen. (2006). Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma. Stem Cells 24:2466-2477.
34. Magatti M, S De Munari, E Vertua, L Gibelli, GS Wengler and O Parolini. (2008). Human amnion mesenchyme harbors cells with allogeneic T-cell suppression and stimulation capabilities. Stem Cells 26:182-192.
35. Banas RA, C Trumpower, C Bentlejewski, V Marshall, G Sing and A Zeevi. (2008). Immunogenicity and immunomodulatory effects of amnion-derived multipotent progenitor cells. Hum Immunol 69:321-328.
36. Nagamatsu T, DJ Schust, J Sugimoto and BF Barrier. (2009). Human decidual stromal cells suppress cytokine secretion by allogenic CD4 + T cells via PD-1 ligand interactions. Hum Reprod 24:3160-3171.
37. Parolini O, F Alviano, GP Bagnara, G Bilic, H-J Bühring, M Evangelista, S Hennerbichler, B Liu, M Magatti, et al. (2008). Concise review: isolation and characterization of cells from human term placenta: outcome of the first international workshop on placenta derived stem cells. Stem Cells 26:300-311.
38. Silini A, O Parolini, B Huppertz and I Lang. (2013). Soluble factors of amnion-derived cells in treatment of inflammatory and fibrotic pathologies. Curr Stem Cell Res Ther 8:6-14.
39. Kubo M, Y Sonoda, R Muramatsu and M Usui. (2001). Immunogenicity of human amniotic membrane in experimental xenotransplantation. Invest Ophthalmol Vis Sci 42:1539-1546.
40. Akle CA, M Adinolfi, KI Welsh, S Leibowitz and I McColl. (1981). Immunogenicity of human amniotic epithelial cells after transplantation into volunteers. Lancet 2:1003-1005.
41. Rodey GE, K Revels and TC Fuller. (1997). Epitope specificity of HLA class I alloantibodies: II. Stability of cross-reactive group antibody patterns over extended time periods. Transplantation 63:885-893.
42. Choi Y, SE Lee, S Fukuda, T Hashimoto and SC Kim. (2011). Mucous membrane pemphigoid with immunoglobulin G autoantibodies against full-length and 120-kDa ectodomain of BP180. J Dermatol 38:169-172.
43. Mogues T, J Li, J Coburn and DJ Kuter. (2005). IgG antibodies against bovine serum albumin in humans-their prevalence and response to exposure to bovine serum albumin. J Immunol Methods 300:1-11.
44. Sjowall C, A Kastbom, G Almroth, J Wettero and T Skogh. (2011). Beware of antibodies to dietary proteins in "antigen-specific" immunoassays! falsely positive anticytokine antibody tests due to reactivity with bovine serum albumin in rheumatoid arthritis (the Swedish TIRA project). J Rheumatol 38:215-220.
45. Debiec H, F Lefeu, MJ Kemper, P Niaudet, G Deschenes, G Remuzzi, T Ulinski and P Ronco. (2011). Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med 364:2101-2110.
46. Krokowski M, S Caillat-Zucman, J Timsit, E Larger, M Pehuet-Figoni, JF Bach and C Boitard. (1995). Anti-bovine serum albumin antibodies: genetic heterogeneity and clinical relevance in adult-onset IDDM. Diabetes Care 18:170-173.
47. Selvaggi TA, RE Walker and TA Fleisher. (1997). Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions. Blood 89:776-779.
48. Spees JL, CA Gregory, H Singh, HA Tucker, A Peister, PJ Lynch, SC Hsu, J Smith and DJ Prockop. (2004). Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther 9:747-756.
49. Rasmusson I,ORingden,B Sundberg andKLe Blanc. (2003). Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 76:1208-1213.